<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Medicine"/>
 <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Biology"/>
 <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Medicine"/>
 <result pre="Alphaviruses: Chikungunya Virus : Medicine and Health Sciences : Tropical" exact="Diseases" post=": Neglected Tropical Diseases: Chikungunya Infection : Medicine and"/>
 <result pre="Health Sciences : Tropical Diseases : Neglected Tropical Diseases: Chikungunya" exact="Infection" post=": Medicine and Health Sciences : Infectious Diseases :"/>
 <result pre="Tropical Diseases: Chikungunya Infection : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Viral Diseases: Chikungunya Infection : Medicine and"/>
 <result pre="Diseases: Chikungunya Infection : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Viral Diseases: Chikungunya Infection : Medicine and Health"/>
 <result pre="Infection : Medicine and Health Sciences : Infectious Diseases :" exact="Viral" post="Diseases: Chikungunya Infection : Medicine and Health Sciences :"/>
 <result pre="and Health Sciences : Infectious Diseases : Viral Diseases: Chikungunya" exact="Infection" post=": Medicine and Health Sciences : Oncology : Cancer"/>
 <result pre="Chikungunya Infection : Medicine and Health Sciences : Oncology :" exact="Cancer" post="Treatment: Proteasome Inhibitors : Biology and Life Sciences :"/>
 <result pre=": Biology and Life Sciences : Biochemistry : Proteins :" exact="Protein" post="Complexes: Proteasomes : Research and analysis methods : Biological"/>
 <result pre="analysis methods : Biological cultures : Cell cultures : Cultured" exact="tumor" post="cells: HeLa cells : Biology and Life Sciences :"/>
 <result pre="cells : Biology and Life Sciences : Microbiology : Virology:" exact="Viral" post="Replication : Biology and Life Sciences : Genetics :"/>
 <result pre=": Biology and Life Sciences : Genetics : Gene Expression:" exact="Protein" post="Translation Bortezomib inhibits chikungunya virus replication by interfering with"/>
 <result pre="Sciences : Genetics : Gene Expression: Protein Translation Bortezomib inhibits" exact="chikungunya" post="virus replication by interfering with viral protein synthesis Bortezomib"/>
 <result pre="Protein Translation Bortezomib inhibits chikungunya virus replication by interfering with" exact="viral" post="protein synthesis Bortezomib inhibits CHIKV KaurParveenConceptualizationData curationFormal analysisInvestigationMethodologyValidationVisualizationWriting –"/>
 <result pre="health threat, there are no approved therapeutics or prophylactics for" exact="CHIKV infection." post="In this study, we explored the anti-CHIKV effects of"/>
 <result pre="panel of proteasome inhibitors with different functional groups reduced CHIKV" exact="infectious" post="titers in a dose-dependent manner. Bortezomib, which has been"/>
 <result pre="in a dose-dependent manner. Bortezomib, which has been FDA-approved for" exact="multiple myeloma" post="and mantle cell lymphoma, was further investigated in downstream"/>
 <result pre="a dose-dependent manner. Bortezomib, which has been FDA-approved for multiple" exact="myeloma" post="and mantle cell lymphoma, was further investigated in downstream"/>
 <result pre="manner. Bortezomib, which has been FDA-approved for multiple myeloma and" exact="mantle cell lymphoma," post="was further investigated in downstream studies. The inhibitory activities"/>
 <result pre="and may display a potential for use as therapeutics against" exact="CHIKV infection." post="They also represent valuable tools for studies of CHIKV"/>
 <result pre="is a mosquito-transmitted virus that causes an illness with debilitating" exact="muscle" post="and joint pain. CHIKV has infected millions in a"/>
 <result pre="Despite this, there are no approved antivirals or vaccines against" exact="CHIKV infection." post="In this study, we explored the inhibitory effects of"/>
 <result pre="progeny virus particles. Bortezomib treatment also prominently increased synthesis of" exact="viral" post="replicase components and increased CHIKV RNA synthesis. We propose"/>
 <result pre="that ultimately lead to a decrease in structural proteins and" exact="infectious" post="viral progeny. This study suggests that proteasome inhibitors display"/>
 <result pre="ultimately lead to a decrease in structural proteins and infectious" exact="viral" post="progeny. This study suggests that proteasome inhibitors display a"/>
 <result pre="inhibitors display a potential for further development as antivirals against" exact="CHIKV infection" post="and may be useful tools to study CHIKV molecular"/>
 <result pre="display a potential for further development as antivirals against CHIKV" exact="infection" post="and may be useful tools to study CHIKV molecular"/>
 <result pre="major public health threat in the last decade [1, 2]." exact="CHIKV infection" post="results in a febrile illness accompanied by debilitating polyarthralgia,"/>
 <result pre="public health threat in the last decade [1, 2]. CHIKV" exact="infection" post="results in a febrile illness accompanied by debilitating polyarthralgia,"/>
 <result pre="accompanied by debilitating polyarthralgia, myalgia and maculopapular rash [3, 4]." exact="Chronic" post="polyarthralgia lasting for several months to years has been"/>
 <result pre="CHIKV, there are currently no licensed therapeutics or prophylactics against" exact="CHIKV infection." post="There remains an urgent need for the discovery of"/>
 <result pre="an urgent need for the discovery of novel antivirals against" exact="CHIKV infection," post="accompanied by an improved understanding of CHIKV replication and"/>
 <result pre="by receptor-mediated endocytosis [15, 16]. Within the host cell, the" exact="viral" post="genome is translated by the eukaryotic translation machinery, producing"/>
 <result pre="then processed into mature proteins. The ns proteins complex with" exact="viral" post="genome and cellular components to form the viral replicase"/>
 <result pre="complex with viral genome and cellular components to form the" exact="viral" post="replicase [17]. The viral replicase generates the full-length negative-sense"/>
 <result pre="and cellular components to form the viral replicase [17]. The" exact="viral" post="replicase generates the full-length negative-sense CHIKV RNA, which serves"/>
 <result pre="CHIKV RNAs [18]. This is followed by translation of the" exact="viral" post="structural proteins from the SG RNA [13]. In the"/>
 <result pre="the plasma membrane, acquiring a lipid envelope to form mature," exact="infectious" post="progeny [19, 20]. The ubiquitin-proteasome system is the major"/>
 <result pre="system has been found to control intracellular levels of certain" exact="viral" post="proteins during replication, including viral proteases, structural proteins and"/>
 <result pre="control intracellular levels of certain viral proteins during replication, including" exact="viral" post="proteases, structural proteins and RNA-dependent RNA polymerase (RdRp) [24]."/>
 <result pre="RNA polymerase (RdRp) [24]. For instance, the proteasomal degradation of" exact="viral" post="proteases has been well documented for picornaviruses, including encephalomyocarditis"/>
 <result pre="has been well documented for picornaviruses, including encephalomyocarditis virus and" exact="hepatitis" post="A virus, [25–27]. Given the role of the viral"/>
 <result pre="and hepatitis A virus, [25–27]. Given the role of the" exact="viral" post="protease in triggering apoptosis, researchers speculate that the UPS"/>
 <result pre="utilized by picornaviruses to maintain sufficiently low levels of the" exact="viral" post="protease during early replication to prevent premature apoptosis [28,"/>
 <result pre="although results differed between studies [34, 35]. For instance, upon" exact="CHIKV infection," post="PSMA6 (proteasome subunit alpha type-6) was reported to be"/>
 <result pre="proteasome inhibitors MG132 and lactacystin resulted in a reduction of" exact="viral" post="titers in CHIKV-infected GripTite 293 MSR cells [36]. In"/>
 <result pre="inhibitors. Bortezomib, a proteasome inhibitor approved for the treatment of" exact="multiple myeloma" post="and mantle cell lymphoma [37, 38], was selected for"/>
 <result pre="Bortezomib, a proteasome inhibitor approved for the treatment of multiple" exact="myeloma" post="and mantle cell lymphoma [37, 38], was selected for"/>
 <result pre="proteasome inhibitor approved for the treatment of multiple myeloma and" exact="mantle cell lymphoma" post="[37, 38], was selected for downstream experiments to investigate"/>
 <result pre="approved for the treatment of multiple myeloma and mantle cell" exact="lymphoma" post="[37, 38], was selected for downstream experiments to investigate"/>
 <result pre="against CHIKV. Further work into their clinical therapeutic use during" exact="CHIKV infection" post="is warranted. Results Proteasome inhibitors suppress CHIKV infection In"/>
 <result pre="CHIKV. Further work into their clinical therapeutic use during CHIKV" exact="infection" post="is warranted. Results Proteasome inhibitors suppress CHIKV infection In"/>
 <result pre="use during CHIKV infection is warranted. Results Proteasome inhibitors suppress" exact="CHIKV infection" post="In order to explore the anti-CHIKV effects of proteasome"/>
 <result pre="during CHIKV infection is warranted. Results Proteasome inhibitors suppress CHIKV" exact="infection" post="In order to explore the anti-CHIKV effects of proteasome"/>
 <result pre="0.1 μM bortezomib onwards resulted in significant inhibition of CHIKV" exact="infectious" post="titer. A maximal 98.5% (2.2 log10 units) inhibition was"/>
 <result pre="no decrease in cell viability, suggesting that bortezomib-mediated reduction in" exact="viral" post="titers were not due to cytotoxicity. A pre-treatment assay"/>
 <result pre="the replication cycle. Fig 1 Effects of bortezomib treatment on" exact="CHIKV infection" post="in BHK21 cells. (A) BHK21 cells were infected with"/>
 <result pre="replication cycle. Fig 1 Effects of bortezomib treatment on CHIKV" exact="infection" post="in BHK21 cells. (A) BHK21 cells were infected with"/>
 <result pre="titers are presented in the bar graphs corresponding to the" exact="primary" post="axis. Cell viability is presented by the line graph"/>
 <result pre="viability is presented by the line graph corresponding to the" exact="secondary" post="axis. Error bars represent standard errors of means from"/>
 <result pre="order to confirm the antiviral effects of proteasome inhibition on" exact="CHIKV infection," post="a panel of proteasome inhibitors from compound classes with"/>
 <result pre="were minimally cytotoxic, indicating that proteasomal inhibition is detrimental to" exact="CHIKV infection." post="The inhibition in CHIKV titers observed for MG132 (Fig"/>
 <result pre="by different proteasomal inhibitors influenced the magnitude of inhibition of" exact="CHIKV infection." post="Fig 2 Effects of proteasome inhibitors on CHIKV infection"/>
 <result pre="of CHIKV infection. Fig 2 Effects of proteasome inhibitors on" exact="CHIKV infection" post="in BHK21 cells. BHK21 cells were infected with CHIKV-122508"/>
 <result pre="CHIKV infection. Fig 2 Effects of proteasome inhibitors on CHIKV" exact="infection" post="in BHK21 cells. BHK21 cells were infected with CHIKV-122508"/>
 <result pre="inhibitors are presented in the bar graphs corresponding to the" exact="primary" post="axis. Percentage inhibition was calculated after normalisation to vehicle"/>
 <result pre="viabilities are presented by the line graph corresponding to the" exact="secondary" post="axis. Error bars represent standard errors of means from"/>
 <result pre="(Fig 3A). The efficacy of bortezomib was also confirmed in" exact="primary" post="human skeletal myoblasts (HSMM), an in vivo target of"/>
 <result pre="primary human skeletal myoblasts (HSMM), an in vivo target of" exact="CHIKV infection" post="[40, 41]. In agreement with results from BHK21 and"/>
 <result pre="human skeletal myoblasts (HSMM), an in vivo target of CHIKV" exact="infection" post="[40, 41]. In agreement with results from BHK21 and"/>
 <result pre="titers are presented in the bar graphs corresponding to the" exact="primary" post="axis. Cell viability is presented by the line graph"/>
 <result pre="viability is presented by the line graph corresponding to the" exact="secondary" post="axis. Error bars for CHIKV-122508 represent standard errors of"/>
 <result pre="titers are presented in the bar graphs corresponding to the" exact="primary" post="axis. Cell viability is presented by the line graph"/>
 <result pre="viability is presented by the line graph corresponding to the" exact="secondary" post="axis. Error bars represent standard errors of means from"/>
 <result pre="while time-of-removal experiments were conducted by adding bortezomib immediately after" exact="infection" post="and removing it at different time-points post-infection. Fig 4"/>
 <result pre="evaluated the possibility that bortezomib affects CHIKV RNA synthesis and/or" exact="viral" post="RNA translation events. To investigate this further, the levels"/>
 <result pre="and treated with either 0.1 μM bortezomib or vehicle control." exact="Protein" post="samples were harvested at different time-points post-infection and probed"/>
 <result pre="and treated with either 0.1 μM bortezomib or vehicle control." exact="Protein" post="samples were harvested at 6 hpi and probed for"/>
 <result pre="nsP3 levels in bortezomib-treated samples were about 20% to 35%" exact="lower" post="than vehicle-treated samples, except for 24 hpi, where it"/>
 <result pre="other time-points, levels of nsP2 was about 20% to 30%" exact="lower" post="than in untreated cells. At 6 hpi, a dose-dependent"/>
 <result pre="monolayer as a result of diminished virion production during each" exact="infection" post="cycle. Western blot analysis showed major elevations in nsP4"/>
 <result pre="are the same treatment concentrations that resulted in reduction of" exact="infectious" post="CHIKV titers for CHIKV-122508 in HeLa cells (Fig 3A)."/>
 <result pre="various proteasome inhibitors at the indicated concentrations or vehicle control." exact="Protein" post="samples were harvested at 6 hpi and probed for"/>
 <result pre="inhibitor-treated samples to vehicle control for each CHIKV protein). Alphavirus" exact="infections" post="are known to induce translational shut-off through a variety"/>
 <result pre="in the presence of eIF2α phosphorylation [46]. However, during early" exact="alphavirus infection," post="eIF2α phosphorylation appears to be inhibited by nsP4, possibly"/>
 <result pre="cells, the levels of phosphorylated (Ser51) eIF2α as well as" exact="total" post="eIF2α were measured in time-point studies. Fig 8 shows"/>
 <result pre="general reduction in levels of phospho-eIF2α over time, with relatively" exact="stable" post="levels of total eIF2α. Strikingly, however, bortezomib treatment in"/>
 <result pre="levels of phospho-eIF2α over time, with relatively stable levels of" exact="total" post="eIF2α. Strikingly, however, bortezomib treatment in mock-infected cells also"/>
 <result pre="the decrease in phospho-eIF2α levels may not be due to" exact="viral" post="ns proteins (including nsP4) accumulation; rather, an alternative pathway"/>
 <result pre="pathway that was activated by bortezomib. Fig 8 Changes in" exact="total" post="and phospho-eIF2α levels upon bortezomib treatment. (A) HeLa cells"/>
 <result pre="and treated with either 0.1 μM bortezomib or vehicle control." exact="Protein" post="samples were harvested at different time-points post-infection and probed"/>
 <result pre="harvested at different time-points post-infection and probed for phospho-eIF2α and" exact="total" post="eIF2α. Western blot images are representative of two independent"/>
 <result pre="effects of bortezomib on CHIKV RNA levels. Bortezomib treatment increased" exact="total" post="CHIKV RNA levels from 12 hpi onwards (Fig 9A),"/>
 <result pre="Samples were harvested at different time-points post-infection for extraction of" exact="total" post="RNA from infected cells. Levels of (A) total CHIKV"/>
 <result pre="extraction of total RNA from infected cells. Levels of (A)" exact="total" post="CHIKV RNA or (B) strand-specific CHIKV RNA were detected"/>
 <result pre="inhibitors from different compound classes were found to reduce CHIKV" exact="infectious" post="titers in a dose-dependent manner. Bortezomib, which has been"/>
 <result pre="manner. Bortezomib, which has been FDA-approved for the treatment of" exact="multiple myeloma" post="and mantle cell lymphoma, showed dose-dependent reductions of CHIKV"/>
 <result pre="Bortezomib, which has been FDA-approved for the treatment of multiple" exact="myeloma" post="and mantle cell lymphoma, showed dose-dependent reductions of CHIKV"/>
 <result pre="has been FDA-approved for the treatment of multiple myeloma and" exact="mantle cell lymphoma," post="showed dose-dependent reductions of CHIKV titers in several cell"/>
 <result pre="protein levels leading to a decrease in progeny virions and" exact="infectious" post="titres. More extensive study would be required to identify"/>
 <result pre="expression levels of a diverse number of cellular proteins and" exact="viral" post="host factors, which may affect CHIKV replication in different"/>
 <result pre="number of different mechanisms. In cells infected with Rift Valley" exact="Fever" post="virus (RVFV), bortezomib reduced the ability of the non-structural"/>
 <result pre="antiviral pathways may have further contributed to the inhibition of" exact="viral" post="replication [48]. As for severe fever with thrombocytopenia syndrome"/>
 <result pre="inhibition of viral replication [48]. As for severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV), a phlebovirus related to RVFV, bortezomib"/>
 <result pre="of viral replication [48]. As for severe fever with thrombocytopenia" exact="syndrome" post="virus (SFTSV), a phlebovirus related to RVFV, bortezomib treatment"/>
 <result pre="bortezomib treatment reversed the degradation of RIG-I induced by the" exact="viral" post="non-structural protein (NS), thereby removing virus-mediated suppression of host"/>
 <result pre="found to inhibit replication of dengue virus, likely by suppressing" exact="viral" post="egress [50]. While the ubiquitin-proteasome system has been found"/>
 <result pre="infected cells. However, by reducing virion production, bortezomib also restricts" exact="viral" post="spread in the monolayer, reducing the overall amounts of"/>
 <result pre="[51]. Apart from translational machinery, the stabilization of host and" exact="viral" post="factors involved in CHIKV replication may have also contributed"/>
 <result pre="degradation of RpbI [53]. This process occurs very early in" exact="infection" post="(within 6 hpi) and is likely to be crucial"/>
 <result pre="inhibition may cause an increase in cellular antiviral responses, restricting" exact="viral" post="replication. As discussed previously, modulation of antiviral responses has"/>
 <result pre="mutant over-produced ns proteins and had somewhat elevated levels of" exact="viral" post="RNA synthesis. Importantly, it also had slightly reduced synthesis"/>
 <result pre="had slightly reduced synthesis of structural proteins and strongly reduced" exact="infectious" post="virion production [55]. These similarities indicate that disrupting the"/>
 <result pre="observed during bortezomib treatment, would have a negative impact on" exact="viral" post="replication. Another important consideration is that a number of"/>
 <result pre="limitation of bortezomib is its narrow therapeutic window [61]. In" exact="cancer" post="patients, the most significant adverse effect reported is peripheral"/>
 <result pre="In cancer patients, the most significant adverse effect reported is" exact="peripheral" post="sensory neuropathy, which is reported in 31% to 55%"/>
 <result pre="cancer patients, the most significant adverse effect reported is peripheral" exact="sensory neuropathy," post="which is reported in 31% to 55% of patients"/>
 <result pre="however, that bortezomib-induced toxicity is related to accumulated dose, with" exact="neuropathy" post="usually surfacing within the first five cycles of treatment,"/>
 <result pre="is six weeks long [37, 59, 63, 64]. However, for" exact="CHIKV infection," post="treatment schedules are not expected to last as long,"/>
 <result pre="are not expected to last as long, given that the" exact="acute" post="phase is resolved within two weeks. Furthermore, altering the"/>
 <result pre="to subcutaneous has been found to significantly reduce instances of" exact="neuropathy" post="in patients, while retaining similar efficacy [37]. In addition,"/>
 <result pre="are able to inhibit CHIKV and cause similar changes to" exact="viral" post="proteins. This indicates that in vivo evaluation of proteasome"/>
 <result pre="of proteasome inhibitors for treatment of CHIKV should not be" exact="limited" post="to bortezomib. Rather, the use of newer generation proteasome"/>
 <result pre="inhibitor such that it is active only upon cleavage by" exact="viral" post="proteases in infected cells. Buckley and colleagues (2011) reported"/>
 <result pre="into the proteasome unless it is cleaved by the human" exact="immunodeficiency" post="virus (HIV) protease [66]. This steric-capped proteasome inhibitor was"/>
 <result pre="of bortezomib and other proteasome inhibitors in the context of" exact="CHIKV infection." post="Extensive optimisations of the modified proteasome inhibitor structure, together"/>
 <result pre="study include BHK21 baby hamster kidney cells (ATCC CCL-10), HeLa" exact="cervical cancer" post="epithelial cells (ATCC CCL-2), human skeletal muscle myoblasts (HSMM,"/>
 <result pre="include BHK21 baby hamster kidney cells (ATCC CCL-10), HeLa cervical" exact="cancer" post="epithelial cells (ATCC CCL-2), human skeletal muscle myoblasts (HSMM,"/>
 <result pre="BHK21 baby hamster kidney cells (ATCC CCL-10), HeLa cervical cancer" exact="epithelial" post="cells (ATCC CCL-2), human skeletal muscle myoblasts (HSMM, Lonza)"/>
 <result pre="CCL-10), HeLa cervical cancer epithelial cells (ATCC CCL-2), human skeletal" exact="muscle" post="myoblasts (HSMM, Lonza) and C6/36 from Aedes albopictus embryonic"/>
 <result pre="10% inactivated FCS. HSMM cells were cultured in SkGM (Skeletal" exact="Muscle" post="Cell Growth Medium, Lonza) with supplied growth factors and"/>
 <result pre="without humidification. This study used two strains of CHIKV East/Central/South" exact="African" post="(ECSA) genotype: CHIKV-122508 (SGEHICHID122508, Accession No.: FJ445502.2) and CHIKV-0708"/>
 <result pre="the plates were frozen at -80°C prior to quantification of" exact="viral" post="titer in cell culture supernatants via plaque assays. Plaque"/>
 <result pre="also performed, where cells were treated with bortezomib prior to" exact="infection" post="with CHIKV. BHK21 monolayers were incubated with various concentrations"/>
 <result pre="titer measured in BHK21 cells and actual level of productive" exact="infection" post="is expected to differ across cell lines [68]. After"/>
 <result pre="μM bortezomib was added at different time-points after the 1.5h" exact="infection" post="period. In time-of-removal experiments, bortezomib was added immediately after"/>
 <result pre="In time-of-removal experiments, bortezomib was added immediately after the 1.5h" exact="infection" post="period and removed at different time-points. Plates from both"/>
 <result pre="with rocking. The cell lysis solution used was M-PER (Mammalian" exact="Protein" post="Extraction Reagent, ThermoFisher Scientific) with added Halt Protease Inhibitor"/>
 <result pre="Samples were thawed on ice and quantitated using the Bio-Rad" exact="Protein" post="Assay Dye Reagent Concentrate according to the manufacturer’s instructions."/>
 <result pre="System (Bio-Rad). Blots were then blocked overnight and incubated with" exact="primary" post="antibodies for 1h while rocking at room temperature. Dilution"/>
 <result pre="nsP4 (1:1000) was diluted in 2% BSA in PBST. After" exact="primary" post="antibody incubation, blots were washed 4 times with TBST"/>
 <result pre="nsP4 blots) for 5 min each before incubation with appropriate" exact="secondary" post="antibodies (goat horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse IgG),"/>
 <result pre="24-well plates (80,000 cells per well) and incubated overnight before" exact="infection" post="with CHIKV-122508 at MOI 10 for 1.5h at 37°C."/>
 <result pre="or vehicle control. Cells were washed once with PBS before" exact="total" post="cellular RNA was extracted using the RNeasy Mini Kit"/>
 <result pre="Res. 2015;120:32–9. 10.1016/j.antiviral.2015.04.01625979669 2WahidB, AliA, RafiqueS, IdreesM. Global expansion of" exact="chikungunya" post="virus: mapping the 64-year history. Int J Infect Dis."/>
 <result pre="Infect Dis. 2017;58:69–76. 10.1016/j.ijid.2017.03.00628288924 3SilvaLA, DermodyTS. Chikungunya virus: epidemiology, replication," exact="disease" post="mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737–49."/>
 <result pre="BreimanRF, PowersAM. Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clin Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid arthritic"/>
 <result pre="infectious disease. Clin Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid" exact="arthritic" post="syndrome after chikungunya fever. S Afr Med J. 1979;56(4):130–2."/>
 <result pre="disease. Clin Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid arthritic" exact="syndrome" post="after chikungunya fever. S Afr Med J. 1979;56(4):130–2. 494034"/>
 <result pre="Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid arthritic syndrome after" exact="chikungunya" post="fever. S Afr Med J. 1979;56(4):130–2. 494034 6JavelleE, RiberaA,"/>
 <result pre="6JavelleE, RiberaA, DegasneI, GauzereBA, MarimoutouC, SimonF. Specific management of post-chikungunya" exact="rheumatic" post="disorders: a retrospective study of 159 cases in Reunion"/>
 <result pre="post-chikungunya rheumatic disorders: a retrospective study of 159 cases in" exact="Reunion Island" post="from 2006–2012.PLoS Negl Trop Dis.2015;9(3):e000360310.1371/journal.pntd.000360325760632 7SchwartzO, AlbertML. Biology and"/>
 <result pre="2006–2012.PLoS Negl Trop Dis.2015;9(3):e000360310.1371/journal.pntd.000360325760632 7SchwartzO, AlbertML. Biology and pathogenesis of" exact="chikungunya" post="virus. Nat Rev Microbiol. 2010;8(7):491–500. 10.1038/nrmicro236820551973 8Fernandez-SalasI, Danis-LozanoR, Casas-MartinezM,"/>
 <result pre="Aedes aegypti as a main contributor of fast dispersal of" exact="chikungunya" post="outbreaks in Latin America. Antiviral Res. 2015;124:30–42. 10.1016/j.antiviral.2015.10.01526518229 9ChenR,"/>
 <result pre="10.1128/JVI.01166-1627654297 10JohanssonMA, PowersAM, PesikN, CohenNJ, StaplesJE. Nowcasting the spread of" exact="chikungunya" post="virus in the Americas.PLoS One.2014;9(8):e10491510.1371/journal.pone.010491525111394 11AmraouiF, FaillouxAB. Chikungunya: an"/>
 <result pre="Biochem Sci. 2000;25(11):544–8. 10.1016/s0968-0004(00)01681-911084366 22GaoG, LuoH. The ubiquitin-proteasome pathway in" exact="viral" post="infections. Can J Physiol Pharmacol. 2006;84(1):5–14. 10.1139/y05-14416845885 23LuoH. Interplay"/>
 <result pre="between the virus and the ubiquitin-proteasome system: molecular mechanism of" exact="viral" post="pathogenesis.Curr Opin Virol. 2016;17:1–10. 10.1016/j.coviro.2015.09.00526426962 24ChoiAG, WongJ, MarchantD, LuoH."/>
 <result pre="24ChoiAG, WongJ, MarchantD, LuoH. The ubiquitin-proteasome system in positive-strand RNA" exact="virus infection." post="Rev Med Virol. 2013;23(2):85–96. 10.1002/rmv.172522782620 25BanerjeeR, WeidmanMK, EcheverriA, KunduP,"/>
 <result pre="accumulation of Turnip yellow mosaic virus RNA-dependent RNA polymerase during" exact="viral infection." post="Plant Cell. 2010;22(9):3142–52. 10.1105/tpc.109.07209020823192 27KerkvlietJ, PapkeL, RodriguezM. Antiviral effects"/>
 <result pre="EvansPE, BastienMC, MichalewichKM, ClarkJK, et al.Identification and Characterization of a" exact="Protein" post="Destruction Signal in the Encephalomyocarditis Virus 3C Protease. J"/>
 <result pre="ZhangJ, LewisE, PlanchartA, LawsonTG. Degradation of the encephalomyocarditis virus and" exact="hepatitis" post="A virus 3C proteases by the ubiquitin/26S proteasome system"/>
 <result pre="Alphaviruses.Viruses. 2019;11(4). 34ThioCL, YusofR, Abdul-RahmanPS, KarsaniSA. Differential proteome analysis of" exact="chikungunya" post="virus infection on host cells.PLoS One. 2013;8(4):e6144410.1371/journal.pone.006144423593481 35AbrahamR, MudaliarP,"/>
 <result pre="2019;11(4). 34ThioCL, YusofR, Abdul-RahmanPS, KarsaniSA. Differential proteome analysis of chikungunya" exact="virus infection" post="on host cells.PLoS One. 2013;8(4):e6144410.1371/journal.pone.006144423593481 35AbrahamR, MudaliarP, JaleelA, SrikanthJ,"/>
 <result pre="34ThioCL, YusofR, Abdul-RahmanPS, KarsaniSA. Differential proteome analysis of chikungunya virus" exact="infection" post="on host cells.PLoS One. 2013;8(4):e6144410.1371/journal.pone.006144423593481 35AbrahamR, MudaliarP, JaleelA, SrikanthJ,"/>
 <result pre="chaperone, Nucleophosmin among the common set of proteins modulated in" exact="Chikungunya virus infection." post="J Proteomics. 2015;120:126–41. 10.1016/j.jprot.2015.03.00725782748 36KarpeYA, PingaleKD, KanadeGD. Activities of"/>
 <result pre="Nucleophosmin among the common set of proteins modulated in Chikungunya" exact="virus infection." post="J Proteomics. 2015;120:126–41. 10.1016/j.jprot.2015.03.00725782748 36KarpeYA, PingaleKD, KanadeGD. Activities of"/>
 <result pre="proteasome and beyond.Curr Pharm Des. 2013;19(22):4025–38. 10.2174/138161281131922001223181572 39SumnerCJ, PaushkinS, KoCP." exact="Spinal" post="Muscular Atrophy: Disease Mechanisms and Therapy: Elsevier Science; 2016."/>
 <result pre="Pharm Des. 2013;19(22):4025–38. 10.2174/138161281131922001223181572 39SumnerCJ, PaushkinS, KoCP. Spinal Muscular Atrophy:" exact="Disease" post="Mechanisms and Therapy: Elsevier Science; 2016. 40HussainKM, LeeRC, NgMM,"/>
 <result pre="Science; 2016. 40HussainKM, LeeRC, NgMM, ChuJJ. Establishment of a Novel" exact="Primary" post="Human Skeletal Myoblast Cellular Model for Chikungunya Virus Infection"/>
 <result pre="Novel Primary Human Skeletal Myoblast Cellular Model for Chikungunya Virus" exact="Infection" post="and Pathogenesis.Sci Rep.2016;6:2140610.1038/srep2140626892458 41OzdenS, Lucas-HouraniM, CeccaldiPE, BasakA, ValentineM, BenjannetS,"/>
 <result pre="Rep.2016;6:2140610.1038/srep2140626892458 41OzdenS, Lucas-HouraniM, CeccaldiPE, BasakA, ValentineM, BenjannetS, et al.Inhibition of" exact="Chikungunya virus infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
 <result pre="41OzdenS, Lucas-HouraniM, CeccaldiPE, BasakA, ValentineM, BenjannetS, et al.Inhibition of Chikungunya" exact="virus infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
 <result pre="Lucas-HouraniM, CeccaldiPE, BasakA, ValentineM, BenjannetS, et al.Inhibition of Chikungunya virus" exact="infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
 <result pre="BenjannetS, et al.Inhibition of Chikungunya virus infection in cultured human" exact="muscle" post="cells by furin inhibitors: impairment of the maturation of"/>
 <result pre="BaileyC, NarayananA. Characterizing the effect of Bortezomib on Rift Valley" exact="Fever" post="Virus multiplication. Antiviral Res. 2015;120:48–56. 10.1016/j.antiviral.2015.05.00426001632 49LiuS, LiuH, ZhangK,"/>
 <result pre="ZhangK, LiX, DuanY, WangZ, et al.Proteasome Inhibitor PS-341 Effectively Blocks" exact="Infection" post="by the Severe Fever with Thrombocytopenia Syndrome Virus.Virol Sin.2019;34(5):572–82."/>
 <result pre="WangZ, et al.Proteasome Inhibitor PS-341 Effectively Blocks Infection by the" exact="Severe" post="Fever with Thrombocytopenia Syndrome Virus.Virol Sin.2019;34(5):572–82. 10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL,"/>
 <result pre="et al.Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe" exact="Fever" post="with Thrombocytopenia Syndrome Virus.Virol Sin.2019;34(5):572–82. 10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL, CostaVV,"/>
 <result pre="Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with" exact="Thrombocytopenia" post="Syndrome Virus.Virol Sin.2019;34(5):572–82. 10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL, CostaVV, TanHC, HorrevortsS,"/>
 <result pre="PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia" exact="Syndrome" post="Virus.Virol Sin.2019;34(5):572–82. 10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL, CostaVV, TanHC, HorrevortsS, OoiEE."/>
 <result pre="10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL, CostaVV, TanHC, HorrevortsS, OoiEE. Proteasome Inhibition Suppresses" exact="Dengue" post="Virus Egress in Antibody Dependent Infection.PLoS Negl Trop Dis.2015;9(11):e000405810.1371/journal.pntd.000405826565697"/>
 <result pre="TanHC, HorrevortsS, OoiEE. Proteasome Inhibition Suppresses Dengue Virus Egress in" exact="Antibody" post="Dependent Infection.PLoS Negl Trop Dis.2015;9(11):e000405810.1371/journal.pntd.000405826565697 51Gonzalez-AlmelaE, SanzMA, Garcia-MorenoM, NorthcoteP,"/>
 <result pre="SokoloskiKJ. Increasing the Capping Efficiency of the Sindbis Virus nsP1" exact="Protein" post="Negatively Affects Viral Infection.mBio. 2018;9(6). 56SchuchmanR, KilianskiA, PiperA, VanciniR,"/>
 <result pre="Capping Efficiency of the Sindbis Virus nsP1 Protein Negatively Affects" exact="Viral" post="Infection.mBio. 2018;9(6). 56SchuchmanR, KilianskiA, PiperA, VanciniR, RibeiroJMC, SpragueTR, et"/>
 <result pre="the Alphaviral Replicase. J Virol. 2018;92(14). 58KimDY, AtashevaS, FrolovaEI, FrolovI." exact="Venezuelan equine encephalitis" post="virus nsP2 protein regulates packaging of the viral genome"/>
 <result pre="Replicase. J Virol. 2018;92(14). 58KimDY, AtashevaS, FrolovaEI, FrolovI. Venezuelan equine" exact="encephalitis" post="virus nsP2 protein regulates packaging of the viral genome"/>
 <result pre="Venezuelan equine encephalitis virus nsP2 protein regulates packaging of the" exact="viral" post="genome into infectious virions. J Virol. 2013;87(8):4202–13. 10.1128/JVI.03142-1223365438 59Arastu-KapurS,"/>
 <result pre="virus nsP2 protein regulates packaging of the viral genome into" exact="infectious" post="virions. J Virol. 2013;87(8):4202–13. 10.1128/JVI.03142-1223365438 59Arastu-KapurS, AnderlJL, KrausM, ParlatiF,"/>
 <result pre="bortezomib and carfilzomib: a link to clinical adverse events. Clin" exact="Cancer" post="Res. 2011;17(9):2734–43. 10.1158/1078-0432.CCR-10-195021364033 60OstrowskaH, WojcikC, WilkS, OmuraS, KozlowskiL, StoklosaT,"/>
 <result pre="the proteasome inhibitor MLN9708 in preclinical models of human cancer." exact="Cancer" post="Res. 2010;70(5):1970–80. 10.1158/0008-5472.CAN-09-276620160034 62RichardsonPG, BriembergH, JagannathS, WenPY, BarlogieB, BerensonJ,"/>
 <result pre="JagannathS, WenPY, BarlogieB, BerensonJ, et al.Frequency, characteristics, and reversibility of" exact="peripheral neuropathy" post="during treatment of advanced multiple myeloma with bortezomib.J Clin"/>
 <result pre="WenPY, BarlogieB, BerensonJ, et al.Frequency, characteristics, and reversibility of peripheral" exact="neuropathy" post="during treatment of advanced multiple myeloma with bortezomib.J Clin"/>
 <result pre="characteristics, and reversibility of peripheral neuropathy during treatment of advanced" exact="multiple myeloma" post="with bortezomib.J Clin Oncol. 2006;24(19):3113–20. 10.1200/JCO.2005.04.777916754936 63AleA, BrunaJ, NavarroX,"/>
 <result pre="and reversibility of peripheral neuropathy during treatment of advanced multiple" exact="myeloma" post="with bortezomib.J Clin Oncol. 2006;24(19):3113–20. 10.1200/JCO.2005.04.777916754936 63AleA, BrunaJ, NavarroX,"/>
 <result pre="substrates. J Am Chem Soc. 2011;133(4):698–700. 10.1021/ja109377p21186803 67KaurP, LeeRC, ChuJJ." exact="Infectious" post="Viral Quantification of Chikungunya Virus-Virus Plaque Assay.Methods Mol Biol."/>
 <result pre="J Am Chem Soc. 2011;133(4):698–700. 10.1021/ja109377p21186803 67KaurP, LeeRC, ChuJJ. Infectious" exact="Viral" post="Quantification of Chikungunya Virus-Virus Plaque Assay.Methods Mol Biol. 2016;1426:93–103."/>
 <result pre="2019;63(4). 69KaurP, ThiruchelvanM, LeeRC, ChenH, ChenKC, NgML, et al.Inhibition of" exact="chikungunya" post="virus replication by harringtonine, a novel antiviral that suppresses"/>
 <result pre="chikungunya virus replication by harringtonine, a novel antiviral that suppresses" exact="viral" post="protein expression. Antimicrob Agents Chemother. 2013;57(1):155–67. 10.1128/AAC.01467-1223275491"/>
</results>
